Sunitinib is a multi-target tyrosine kinase inhibitor with antitumor activity has been identified as a potent inhibitor of PDGFR, VEGFR, RET, and FMS-like tyrosine kinase 3 (FLT3), and it is being used for imatinib-resistant GIST as well as advanced RCC [43]. Here, PDGFRB is linked to renal cell carcinoma.